| Pt ID | time after HSCT, months | treatment specificity | ELISpot positivity for IFNγ, days | resolution of viremia, days | increase in CD3 + CD45RA-CD197- effector memory cell counts | condition before the treatment | clinical response |
|---|---|---|---|---|---|---|---|
| Pt 1 | 19 | CMV | 14 (CMV) | 28 | - | CMV viremia, active CMV retinitis | alleviation of CMV viremia and CMV retinitis |
| Pt 2 | 3 | CMV, ADV, SARS-CoV-2, BKV (LT, Vp1) | 28 (CMV, ADV, BKV) | 60 | + | CMV viremia, BK viremia | alleviation of CMV and BKV viremia |
| Pt 3 | 9 | CMV, ADV, SARS-CoV-2, BKV (LT, Vp1) | - | - | + | persistent BKV viruria, BKV viremia | no improvement |
| Pt 4 | 1 | CMV, ADV, SARS-CoV-2 | 28 (SARS-CoV-2) | 28 | + | COVID-19 pneumonia | SARS-CoV-2 clearance |
| Pt 5 | 5 | CMV, ADV, SARS-CoV-2, BKV (LT, Vp1) | 28 (CMV, ADV, SARS-CoV-2, BKV) | - | + | severe hypofunction of the graft, pancytopenia; viral damage to hematopoiesis, BKV-associated | alleviation of symptoms, viral clearance |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.